RT Journal Article SR Electronic T1 Physical Activity, Sleep, and Quality of Life in Pulmonary Arterial Hypertension: Novel Insights from Wearable Devices JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.09.30.24314671 DO 10.1101/2024.09.30.24314671 A1 Hughes, Andrew M. A1 Lindsey, Alisha A1 Annis, Jeffrey A1 Burke, Kelly A1 Master, Hiral A1 Silverman-Lloyd, Luke G. A1 Garry, Jonah D. A1 Blaha, Michael J. A1 Berman Rosenzweig, Erika S. A1 Frantz, Robert P. A1 Hassoun, Paul M. A1 Horn, Evelyn M. A1 Leopold, Jane A. A1 Rischard, Franz P. A1 Larive, Brett A1 Hill, Nicholas S. A1 Erzurum, Serpil C. A1 Beck, Gerald J. A1 Hemnes, Anna R. A1 Brittain, Evan L. YR 2024 UL http://medrxiv.org/content/early/2024/10/01/2024.09.30.24314671.abstract AB Background Reduced functional capacity and poor sleep quality are common in pulmonary arterial hypertension (PAH). We aimed to determine whether Fitbit-derived activity and sleep trends provide clinically meaningful information in patients with PAH.Methods Our prospective observational study recruited patients with PAH from across the United States. Participants with PAH wore a Fitbit device for 12-weeks at baseline and a subgroup with one-year follow-up. A matched control cohort was generated from the All of Us Research Program and we evaluated changes in patients with PAH compared to matched controls.Results Among 109 patients with baseline monitoring, average daily steps correlated with 6MWD (r=0.66, p < 0.001) and percent rapid eye movement (REM) sleep (r=0.26, p=0.016). In 44 PAH participants who completed baseline and one-year monitoring, there was a group-time interaction for percent light sleep (p=0.024) and percent REM sleep (p=0.034), which demonstrated that sleep quality worsened in patients with PAH over one year compared to matched controls. Average daily steps in patients with PAH decreased from 5200 [IQR 3212 – 7458] at baseline to 4651 [IQR 2912 – 6827] at one year (p=0.008). Compared to matched controls, activity levels were significantly lower in patients with PAH at both time points.Conclusions Our study demonstrated the potential clinical value of wearable devices by showing that activity and sleep quality are reduced in PAH compared to matched controls and these measures decline over time. Future studies should investigate if monitoring these health behaviors detects early functional decline and whether targeted interventions may improve outcomes.Prior Abstract Publication/Presentation Some of the data presented in this manuscript have been included in the following abstracts: Hughes A, Annis J, Hemnes A, Lindsey A, Burke K, Brittain E, and the PVDOMICS Study Group. Sleep Patterns and Quality of Life in Pulmonary Arterial Hypertension. Presented at the American Heart Association (AHA) Scientific Sessions, November 2023, Philadelphia, PA.Hughes A, Annis J, Hemnes A, Lindsey A, Burke K, Horn EM, Brittain E, and the PVDOMICS Study Group. The Role of Long-Term Daily Activity Monitoring for the Assessment of Functional Capacity in Pulmonary Arterial Hypertension. Presented at the American Thoracic Society International Conference, May 2023, Washington D.C.Hughes A, Annis J, Hemnes A, Lindsey A, Burke K, Horn EM, Brittain E, and the PVDOMICS Study Group. Long-Term Daily Activity is Associated with Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension. Presented at the American Heart Association (AHA) Scientific Sessions, November 2022, Chicago, IL.Competing Interest StatementThe authors have declared no competing interest.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Vanderbilt University Medical Center Institutional Review Board (IRB).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData for this study can be made available through data use agreements with Vanderbilt and the PVDOMICS program. All data from All of Us are publicly available.AoURPAll of Us Research ProgramBMIBody Mass IndexL-PVDOMICSLongitudinal Pulmonary Vascular Disease Phenomics ProgramMLHFMinnesota Living with Heart Failure QuestionnairePAHPulmonary Arterial HypertensionQOLQuality of LifeREMRapid Eye MovementWHOWorld Health Organization6MWD6 Minute Walk Distance6MWT6 Minute Walk Test